Tacrolimus Microemulsion Has Good Efficacy, Safety for Scalp Psoriasis
By Elana Gotkine HealthDay Reporter
TUESDAY, March 5, 2024 -- For scalp psoriasis, 0.1 percent tacrolimus microemulsion has good efficacy and safety, according to a study published online Feb. 12 in Dermatology and Therapy.
Andreas Pinter, M.D., from the University Hospital Frankfurt in Germany, and colleagues conducted a multicenter, double-blind, vehicle-controlled phase 3 trial to examine the efficacy and safety of 0.1 percent tacrolimus microemulsion when applied topically in 128 patients with scalp psoriasis.
The researchers found that at eight weeks, scalp Investigator Global Assessment of 0 or 1 occurred in 28.6 percent of individuals in the tacrolimus group compared with 12.7 percent in the placebo group, indicating a significantly better response. Over time, the Dermatology Life Quality Index improved and was more pronounced in the tacrolimus- versus the placebo-treated group; after eight weeks of use, the difference was not statistically significant. No evidence of cutaneous side effects other than those known were revealed in the safety analysis. The study could not exclude toxicologically relevant serum levels of tacrolimus.
"In general, the results of this study are in line with a 2016 review of at least 23 studies involving more than 800 subjects evaluating topically applied tacrolimus, showing its general efficacy in treating different types of psoriasis in different areas," the authors write.
Preparation of this article was supported by a grant from Bay Pharma.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted March 2024
Read this next
Tobacco Smoking Reduces the Odds of Psoriasis Improvement
WEDNESDAY, April 24, 2024 -- Tobacco smoking is negatively associated with resolution of psoriasis symptoms, according to a study published in the April issue of Tobacco Induced...
AAD: Bimekizumab Response Durable at Four Years for Moderate-to-Severe Psoriasis
FRIDAY, March 15, 2024 -- Patients with psoriasis treated with bimekizumab rapidly achieve high levels of clinical and health-related quality-of-life responses that are...
Deep Learning Improves Diagnostic Accuracy for Skin Diseases
FRIDAY, Feb. 16, 2024 -- Deep learning-aided decision support improves diagnostic accuracy for skin disease, according to a study published online Feb. 5 in Nature...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.